<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">02445</article-id><article-id pub-id-type="doi">10.7554/eLife.02445</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-11207"><name><surname>Choi</surname><given-names>Young Eun</given-names></name><aff><addr-line><named-content content-type="department">Department of Radiation Oncology, Division of Genomic Stability and DNA Repair</named-content></addr-line>, <institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-11211"><name><surname>Pan</surname><given-names>Yunfeng</given-names></name><aff><addr-line><named-content content-type="department">Department of Radiation Oncology, Division of Genomic Stability and DNA Repair</named-content></addr-line>, <institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-11208"><name><surname>Park</surname><given-names>Eunmi</given-names></name><aff><addr-line><named-content content-type="department">Department of Radiation Oncology, Division of Genomic Stability and DNA Repair</named-content></addr-line>, <institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-11209"><name><surname>Konstantinopoulos</surname><given-names>Panagiotis</given-names></name><aff><addr-line><named-content content-type="department">Department of Medical Oncology</named-content></addr-line>, <institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-11212"><name><surname>De</surname><given-names>Subhajyoti</given-names></name><aff><addr-line><named-content content-type="department">Department of Medicine</named-content></addr-line>, <institution>University of Colorado School of Medicine</institution>, <addr-line><named-content content-type="city">Aurora</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-11210"><name><surname>D'Andrea</surname><given-names>Alan</given-names></name><aff><addr-line><named-content content-type="department">Department of Radiation Oncology,  Division of Genomic Stability and DNA Repair</named-content></addr-line>, <institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-11010"><name><surname>Chowdhury</surname><given-names>Dipanjan</given-names></name><aff><addr-line><named-content content-type="department">Department of Radiation Oncology, Division of Genomic Stability and DNA Repair</named-content></addr-line>, <institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country><email>dipanjan_chowdhury@dfci.harvard.edu</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1150"><name><surname>Nilsen</surname><given-names>Timothy</given-names></name><role>Reviewing editor</role><aff><institution>Case Western Reserve University</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>30</day><month>04</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e02445</elocation-id><supplementary-material><ext-link xlink:href="elife-02445-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>02</day><month>02</month><year>2014</year></date><date date-type="accepted"><day>29</day><month>04</month><year>2014</year></date></history><permissions><copyright-statement>Copyright Â© 2014, Choi et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Choi et al</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Homologous recombination (HR) mediated repair of DNA double-strand break (DSB)s is restricted to the post-replicative phases of the cell cycle. Initiation of HR in the G1 phase blocks non-homologous end joining (NHEJ) impairing DSB repair. Completion of HR in G1 cells can lead to the loss-of-heterozygosity (LOH) which is potentially carcinogenic. We conducted a gain-of-function screen to identify miRNAs that regulate HR-mediated DSB repair, and of these miRNAs, miR-1255b, miR-148b*and miR-193b* specifically suppress the HR-pathway in the G1 phase. These miRNAs target the transcripts of HR factors, BRCA1, BRCA2 and RAD51 and inhibiting miR-1255b, miR-148b*and miR-193b* increases expression of BRCA1/BRCA2/RAD51 specifically in the G1-phase leading to impaired DSB repair. Depletion of CtIP, a BRCA1-associated DNA end resection protein, rescues this phenotype. Furthermore, deletion of miR-1255b, miR-148b*and miR-193b* in independent cohorts of ovarian tumors correlates with significant increase in LOH events/ chromosomal aberrations and BRCA1 expression.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The clinical data from patients was obtained via published sources which include the Cancer Genome Atlas</p></fn></fn-group></back></article>